약물방출 스텐트 시술을 받은 급성 심근경색증 환자에서 항인지질 항체의 존재가 주요 심혈관 사건에 미치는 영향 = Relationship between Antiphospholipid Antibodies and Major Adverse Cardiovascular Events after Drug-Eluting Stent Implantation in Patients with Acute Myocardial Infarction

다국어 초록 (Multilingual Abstract)

Background/Aims: Several studies have reported an association between antiphospholipid antibodies (APA) and major adverse cardiovascular events (MACE) following acute myocardial infarction (AMI). However, the relationship between APA and the prognosis after drug-eluting stent (DES) implantation in patients with AMI is not known. Methods: Thus, we investigated the relationship between the incidence of MACE and APA levels in patients with AMI who underwent successful DES implantation. Results: Of 182 patients, 78 (42.9%) tested positive for APA. Lupus anticoagulant was positive in 37.6% (68 of 181) patients, anticardiolipin antibody IgM was positive in 8.3% (15 of 180), and anticardiolipin antibody IgG was positive in 1.7% (3 of 180) patients. At follow up, a MACE had occurred in 11 (14.1%) patients in the APA-positive group and in seven (6.7%) patients in the APA-negative group (p = 0.099). Conclusions: No significant association was found between the incidence of MACE and the presence of APA in patients with AMI who underwent successful DES implantation. (Korean J Med 2013;84:681-689)

참고문헌 (Reference)

1 Niessner A, "qPre-existing anticardiolipin antibodies and development of restenosis after coronary balloon angioplasty: predictive value for a complicated course?" 15 : 311-316, 2004

2 Iakovou I, "and outcome of thrombosis after successful implantation of drug-eluting stents" 293 : 2126-2130, 2005

3 Brar SS, "Use of drug-eluting stents in acute myocardial infarction : a systematic review and meta-analysis" 53 : 1677-1689, 2009

4 Killip T 3rd, "Treatment of myocardial infarction in a coronary care unit : a two year experience with 250 patients" 20 : 457-464, 1967

5 Long BR, "The role of antiphospholipid syndrome in cardiovascular disease" 22 : 79-94, 2008

6 Petri M, "The lupus anticoagulant is a risk factor for myocardial infarction(but not atherosclerosis) : Hopkins Lupus Cohort" 114 : 593-595, 2004

7 Acar G, "Recurrent acute stent thrombosis associated with protein C and S deficiencies" 22 : 333-337, 2006

8 Greco TP, "Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome" 132 : 613-620, 2009

9 Chiarugi L, "Lipoprotein (a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty" 154 : 129-135, 2001

10 Vuilleumier N, "Head-to-head comparison of auto-antibodies for cardiovascular outcome prediction after myocardial infarction: a prospective study" 2 : 169-, 2011

11 Petri M, "Epidemiology of the antiphospholipid antibody syndrome" 15 : 145-151, 2000

12 Vianna JL, "Comparison of the primary and secondary antiphospholipid syndrome : a European Multicenter Study of 114 patients" 96 : 3-9, 1994

13 Kalesan B, "Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction" 33 : 977-987, 2012

14 Cutlip DE, "Clinical end points in coronary stent trials : a case for standardized definitions" 115 : 2344-2351, 2007

15 Sharma S, "Association of anticardiolipin antibodies levels with instent restenosis in patients with coronary artery disease" 52 : 288-292, 2008

16 Gürlek A, "Association between anticardiolipin antibodies and recurrent cardiac events in patients with acute coronary syndrome" 46 : 631-638, 2005

17 Weissman A, "Antiphospholipid antibody syndrome and acute stent thrombosis" 7 : 244-246, 2006

18 Urbanus RT, "Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study : a case-control study" 8 : 998-1005, 2009

19 Sletnes KE, "Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke" 339 : 451-453, 1992

20 Eber B, "Anticardiolipin antibodies are no marker for survived myocardial infarction" 68 : 594-596, 1990

21 Bili A, "Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients: Thrombogenic Factors, and Recurrent Coronary Events Investigators" 102 : 1258-1263, 2000

22 Zuckerman E, "Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythmatosus patients: a controlled prospective study" 104 : 381-386, 1996

23 Vaarala O, "Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men" 91 : 23-27, 1995

24 Vaarala O, "Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men" 91 : 23-27, 1995

25 Su HM, "Acute thrombosis after elective direct intracoronary stenting in primary antiphospholipid syndrome : a case report" 19 : 177-182, 2003

26 Turgut T, "Acute coronary occlusion and in-stent thrombosis in a patient with essential thrombocythemia" 45 : 428-433, 1998